Spots Global Cancer Trial Database for Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
Official Title: A Single-arm, Multicenter, Phase II Study to Evaluate Candonilimab（AK104） Combined With Radiotherapy For The Treatment of Locally Advanced Cervical Cancer
Study ID: NCT05687851
Conditions
Study Description
Brief Summary: Candonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4. This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of candonilimab plus radiotherapy in participants with locally advanced cervical cancer who do not tolerate chemotherapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Chongqing university Cancer Hospital, Chongqing, CHN, China
Contact Details
Name: Qi Zhou, MD
Affiliation: Chongqing University Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
